메뉴 건너뛰기




Volumn 4, Issue 2, 2010, Pages 147-156

Valganciclovir in pediatric organ transplantation

Author keywords

Children; Cytomegalovirus; Ganciclovir; Pharmacokinetics; Transplant; Valganciclovir

Indexed keywords

DNA POLYMERASE; GANCICLOVIR; PRODRUG; PROTEIN UL54; UL97 KINASE; UNCLASSIFIED DRUG; VALGANCICLOVIR; VIRUS DNA; VIRUS ENZYME;

EID: 77950508496     PISSN: 17455111     EISSN: None     Source Type: Journal    
DOI: 10.2217/phe.10.16     Document Type: Review
Times cited : (1)

References (39)
  • 2
    • 0029782102 scopus 로고    scopus 로고
    • Cytomegalovirus infection following liver transplantation: Review of the literature
    • Kanj SS, Sharara AI, Clavien PA, Hamilton JD: Cytomegalovirus infection following liver transplantation: review of the literature. Clin. Infect. Dis. 22, 537-549 (1996). (Pubitemid 26259186)
    • (1996) Clinical Infectious Diseases , vol.22 , Issue.3 , pp. 537-549
    • Kanj, S.S.1    Sharara, A.I.2    Clavien, P.-A.3    Hamilton, J.D.4
  • 3
    • 0028353446 scopus 로고
    • Prophylaxis of primary cytomegalovirus disease in renal transplant recipients: A trial of ganciclovir vs immunoglobulin
    • Conti DJ, Freed BM, Gruber SA, Lempert N: Prophylaxis of primary cytomegalovirus disease in renal transplant recipients. A trial of ganciclovir vs immunoglobulin. Arch. Surg. 129, 443-447 (1994). (Pubitemid 24115966)
    • (1994) Archives of Surgery , vol.129 , Issue.4 , pp. 443-447
    • Conti, D.J.1    Freed, B.M.2    Gruber, S.A.3    Lempert, N.4
  • 4
    • 0024361608 scopus 로고
    • A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts
    • Balfour J, Henry H, Chace BA, Stapleton JT, Simmons RL, Fryd DS: A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N. Engl. J. Med. 320(21), 1381-1388 (1989). (Pubitemid 19138933)
    • (1989) New England Journal of Medicine , vol.320 , Issue.21 , pp. 1381-1387
    • Balfour Jr., H.H.1    Chace, B.A.2    Stapleton, J.T.3    Simmons, R.L.4    Fryd, D.S.5
  • 5
    • 0033551348 scopus 로고    scopus 로고
    • Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group
    • Lowance D, Neumayer HH, Legendre CM et al.: Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N. Engl. J. Med. 340(19), 1462-1470 (1999).
    • (1999) N. Engl. J. Med. , vol.340 , Issue.19 , pp. 1462-1470
    • Lowance, D.1    Neumayer, H.H.2    Legendre, C.M.3
  • 6
    • 0031581506 scopus 로고    scopus 로고
    • Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients
    • The Oral Ganciclovir International Transplantation Study Group [corrected]
    • Gane E, Saliba F, Valdecasas GJ et al.: Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 350(9093), 1729-1733 (1997).
    • (1997) Lancet , vol.350 , Issue.9093 , pp. 1729-1733
    • Gane, E.1    Saliba, F.2    Valdecasas, G.J.3
  • 7
    • 1942469969 scopus 로고    scopus 로고
    • Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients
    • Paya C, Humar A, Dominguez E et al.: Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant. 4(4), 611-620 (2004).
    • (2004) Am. J. Transplant. , vol.4 , Issue.4 , pp. 611-620
    • Paya, C.1    Humar, A.2    Dominguez, E.3
  • 9
    • 0024041143 scopus 로고
    • Antiviral activity and mechanism of action of ganciclovir
    • Matthews T, Boehme R: Antiviral activity and mechanism of action of ganciclovir. Rev. Infect. Dis. 10(Suppl. 3), S490-S494 (1988).
    • (1988) Rev. Infect. Dis. , vol.10 , Issue.SUPPL. 3
    • Matthews, T.1    Boehme, R.2
  • 11
    • 0036137356 scopus 로고    scopus 로고
    • High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy
    • Limaye AP, Raghu G, Koelle DM, Ferrenberg J, Huang ML, Boeckh M: High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J. Infect. Dis. 185(1), 20-27 (2002).
    • (2002) J. Infect. Dis. , vol.185 , Issue.1 , pp. 20-27
    • Limaye, A.P.1    Raghu, G.2    Koelle, D.M.3    Ferrenberg, J.4    Huang, M.L.5    Boeckh, M.6
  • 12
    • 0034686916 scopus 로고    scopus 로고
    • Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants
    • Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M: Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356(9230), 645-649 (2000).
    • (2000) Lancet , vol.356 , Issue.9230 , pp. 645-649
    • Limaye, A.P.1    Corey, L.2    Koelle, D.M.3    Davis, C.L.4    Boeckh, M.5
  • 13
    • 0032573205 scopus 로고    scopus 로고
    • Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function
    • Pescovitz MD, Pruett TL, Gonwa T et al.: Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. Transplantation 66, 1104-1107 (1998).
    • (1998) Transplantation , vol.66 , pp. 1104-1107
    • Pescovitz, M.D.1    Pruett, T.L.2    Gonwa, T.3
  • 14
    • 0033801280 scopus 로고    scopus 로고
    • Membrane transporters
    • Lee VH: Membrane transporters. Eur. J. Pharm. Sci. 11(Suppl. 2), S41-S50 (2000).
    • (2000) Eur. J. Pharm. Sci. , vol.11 , Issue.SUPPL. 2
    • Lee, V.H.1
  • 16
    • 0031981201 scopus 로고    scopus 로고
    • Carrier-mediated intestinal absorption of valacyclovir, the l-valyl ester prodrug of acyclovir: 1. Interactions with peptides, organic anions and organic cations in rats
    • Sinko PJ, Balimane PV: Carrier-mediated intestinal absorption of valacyclovir, the l-valyl ester prodrug of acyclovir: 1. Interactions with peptides, organic anions and organic cations in rats. Biopharm. Drug Dispos. 19, 209-217 (1998).
    • (1998) Biopharm. Drug Dispos. , vol.19 , pp. 209-217
    • Sinko, P.J.1    Balimane, P.V.2
  • 17
    • 47649088674 scopus 로고    scopus 로고
    • Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir
    • Chou S: Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev. Med. Virol. 18(4), 233-246 (2008).
    • (2008) Rev. Med. Virol. , vol.18 , Issue.4 , pp. 233-246
    • Chou, S.1
  • 18
    • 0036628639 scopus 로고    scopus 로고
    • Stability of valganciclovir in an extemporaneously compounded oral liquid
    • Anaizi NH, Dentinger PJ, Swenson CF: Stability of valganciclovir in an extemporaneously compounded oral liquid. Am. J. Health Syst. Pharm. 59(13), 1267-1270 (2002).
    • (2002) Am. J. Health Syst. Pharm. , vol.59 , Issue.13 , pp. 1267-1270
    • Anaizi, N.H.1    Dentinger, P.J.2    Swenson, C.F.3
  • 19
    • 37049016433 scopus 로고    scopus 로고
    • Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation
    • Pescovitz MD, Jain A, Robson R, Mulgaonkar S, Freeman R, Bouw MR: Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation. Transplant. Proc. 39(10), 3111-3116 (2007).
    • (2007) Transplant. Proc. , vol.39 , Issue.10 , pp. 3111-3116
    • Pescovitz, M.D.1    Jain, A.2    Robson, R.3    Mulgaonkar, S.4    Freeman, R.5    Bouw, M.R.6
  • 20
    • 33645110301 scopus 로고    scopus 로고
    • Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients
    • Park JM, Lake KD, Arenas JD, Fontana RJ: Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Liver Transpl. 12, 112-116 (2005).
    • (2005) Liver Transpl. , vol.12 , pp. 112-116
    • Park, J.M.1    Lake, K.D.2    Arenas, J.D.3    Fontana, R.J.4
  • 21
    • 26444437323 scopus 로고    scopus 로고
    • Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    • Jain A, Orloff M, Kashyap R et al.: Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients? Transplant. Proc. 37(7), 3182-3186 (2005).
    • (2005) Transplant. Proc. , vol.37 , Issue.7 , pp. 3182-3186
    • Jain, A.1    Orloff, M.2    Kashyap, R.3
  • 22
    • 65849405940 scopus 로고    scopus 로고
    • Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: An evidence-based reassessment of safety and efficacy
    • Kalil AC, Freifeld AG, Lyden ER, Stoner JA: Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy. PLoS ONE 4(5), E5512 (2009).
    • (2009) PLoS ONE , vol.4 , Issue.5
    • Kalil, A.C.1    Freifeld, A.G.2    Lyden, E.R.3    Stoner, J.A.4
  • 23
    • 77950468641 scopus 로고    scopus 로고
    • The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients
    • In press
    • Humar A, Lebranchu Y, Vincenti F et al.: The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am. J. Transplant. (2010) (In press).
    • (2010) Am. J. Transplant.
    • Humar, A.1    Lebranchu, Y.2    Vincenti, F.3
  • 24
    • 65249181619 scopus 로고    scopus 로고
    • Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients
    • Asberg A, Humar A, Jardine AG et al.: Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am. J. Transplant. 9(5), 1205-1213 (2009).
    • (2009) Am. J. Transplant. , vol.9 , Issue.5 , pp. 1205-1213
    • Asberg, A.1    Humar, A.2    Jardine, A.G.3
  • 25
    • 34547829434 scopus 로고    scopus 로고
    • Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients
    • Asberg A, Humar A, Rollag H et al.: Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant. 7(9), 2106-2113 (2007).
    • (2007) Am. J. Transplant. , vol.7 , Issue.9 , pp. 2106-2113
    • Asberg, A.1    Humar, A.2    Rollag, H.3
  • 26
    • 2442648883 scopus 로고    scopus 로고
    • Valganciclovir for the prophylaxis of cytomegalovirus disease in pediatric liver transplant recipients
    • Clark BS, Chang IF, Karpen SJ et al.: Valganciclovir for the prophylaxis of cytomegalovirus disease in pediatric liver transplant recipients. Transplantation 77(9), 1480 (2004).
    • (2004) Transplantation , vol.77 , Issue.9 , pp. 1480
    • Clark, B.S.1    Chang, I.F.2    Karpen, S.J.3
  • 27
    • 10744221566 scopus 로고    scopus 로고
    • Variability in standard care for cytomegalovirus prevention and detection in pediatric lung transplantation: Survey of eight pediatric lung transplant programs
    • Danziger-Isakov LA, Faro A, Sweet S et al.: Variability in standard care for cytomegalovirus prevention and detection in pediatric lung transplantation: survey of eight pediatric lung transplant programs. Pediatr. Transplant. 7(6), 469-473 (2003).
    • (2003) Pediatr. Transplant. , vol.7 , Issue.6 , pp. 469-473
    • Danziger-Isakov, L.A.1    Faro, A.2    Sweet, S.3
  • 28
    • 34147102808 scopus 로고    scopus 로고
    • Unexpectedly high inter- and intrapatient variability of ganciclovir levels in children
    • Vethamuthu J, Feber J, Chretien A, Lampe D, Filler G: Unexpectedly high inter- and intrapatient variability of ganciclovir levels in children. Pediatr. Transplant. 11(3), 301-305 (2007).
    • (2007) Pediatr. Transplant. , vol.11 , Issue.3 , pp. 301-305
    • Vethamuthu, J.1    Feber, J.2    Chretien, A.3    Lampe, D.4    Filler, G.5
  • 29
    • 0033807143 scopus 로고    scopus 로고
    • Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients
    • Pescovitz MD, Rabkin J, Merion RM et al.: Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob. Agents Chemother. 44(10), 2811-2815 (2000).
    • (2000) Antimicrob. Agents Chemother. , vol.44 , Issue.10 , pp. 2811-2815
    • Pescovitz, M.D.1    Rabkin, J.2    Merion, R.M.3
  • 30
    • 67650251911 scopus 로고    scopus 로고
    • Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients
    • Zhao W, Baudouin V, Zhang D, Deschenes G, Guellec CL, Jacqz-Aigrain E: Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients. Clin. Pharmacokinet. 48(5), 321-328 (2009).
    • (2009) Clin. Pharmacokinet. , vol.48 , Issue.5 , pp. 321-328
    • Zhao, W.1    Baudouin, V.2    Zhang, D.3    Deschenes, G.4    Guellec, C.L.5    Jacqz-Aigrain, E.6
  • 31
    • 77950510829 scopus 로고    scopus 로고
    • Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients
    • DOI:10.1111/j.1399-3062.2009.00478.x Epub ahead of print
    • Pescovitz MD, Ettenger RB, Strife CF et al.: Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients. Transpl. Infect. Dis. DOI:10.1111/j.1399-3062.2009. 00478.x (2010) (Epub ahead of print).
    • (2010) Transpl. Infect. Dis.
    • Pescovitz, M.D.1    Ettenger, R.B.2    Strife, C.F.3
  • 32
    • 60749110137 scopus 로고    scopus 로고
    • Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients
    • Vaudry W, Ettenger R, Jara P et al.: Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. Am. J. Transplant. 9(3), 636-643 (2009).
    • (2009) Am. J. Transplant. , vol.9 , Issue.3 , pp. 636-643
    • Vaudry, W.1    Ettenger, R.2    Jara, P.3
  • 33
    • 20544469697 scopus 로고    scopus 로고
    • Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients
    • Wiltshire H, Paya CV, Pescovitz MD et al.: Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 79(11), 1477-1483 (2005).
    • (2005) Transplantation , vol.79 , Issue.11 , pp. 1477-1483
    • Wiltshire, H.1    Paya, C.V.2    Pescovitz, M.D.3
  • 34
    • 21144452373 scopus 로고    scopus 로고
    • Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients
    • Wiltshire H, Hirankarn S, Farrell C et al.: Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin. Pharmacokinet. 44(5), 495-507 (2005).
    • (2005) Clin. Pharmacokinet. , vol.44 , Issue.5 , pp. 495-507
    • Wiltshire, H.1    Hirankarn, S.2    Farrell, C.3
  • 35
    • 49649097948 scopus 로고    scopus 로고
    • Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus
    • Hierro L, Diez-Dorado R, Diaz C et al.: Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus. Liver Transpl. 14(8), 1185-1193 (2008).
    • (2008) Liver Transpl. , vol.14 , Issue.8 , pp. 1185-1193
    • Hierro, L.1    Diez-Dorado, R.2    Diaz, C.3
  • 36
    • 64349090453 scopus 로고    scopus 로고
    • Impact of valganciclovir on Epstein-Barr Virus polymerase chain reaction in pediatric liver transplantation: Preliminary report
    • Venturi C, Bueno J, Gavalda J et al.: Impact of valganciclovir on Epstein-Barr Virus polymerase chain reaction in pediatric liver transplantation: preliminary report. Transplant. Proc. 41(3), 1038-1040 (2009).
    • (2009) Transplant. Proc. , vol.41 , Issue.3 , pp. 1038-1040
    • Venturi, C.1    Bueno, J.2    Gavalda, J.3
  • 37
    • 0035008468 scopus 로고    scopus 로고
    • The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation
    • Green M, Reyes J, Webber S, Rowe D: The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation. Transpl. Infect. Dis. 3(2), 97-103 (2001).
    • (2001) Transpl. Infect. Dis. , vol.3 , Issue.2 , pp. 97-103
    • Green, M.1    Reyes, J.2    Webber, S.3    Rowe, D.4
  • 38
    • 32344451537 scopus 로고    scopus 로고
    • Neurotoxicity related to valganciclovir in a child with impaired renal function: Usefulness of therapeutic drug monitoring
    • Peyriere H, Jeziorsky E, Jalabert A et al.: Neurotoxicity related to valganciclovir in a child with impaired renal function: usefulness of therapeutic drug monitoring. Ann. Pharmacother. 40(1), 143-146 (2006).
    • (2006) Ann. Pharmacother. , vol.40 , Issue.1 , pp. 143-146
    • Peyriere, H.1    Jeziorsky, E.2    Jalabert, A.3
  • 39
    • 0030824419 scopus 로고    scopus 로고
    • Ganciclovir induces reproductive hazards in male rats after short-term exposure
    • Faqi AS, Klug A, Merker HJ, Chahoud I: Ganciclovir induces reproductive hazards in male rats after short-term exposure. Hum. Exp. Toxicol. 16(9), 505-511 (1997).
    • (1997) Hum. Exp. Toxicol. , vol.16 , Issue.9 , pp. 505-511
    • Faqi, A.S.1    Klug, A.2    Merker, H.J.3    Chahoud, I.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.